Abstract

The treatment of chronic coronary artery disease has evolved over decades. AHA/ ACC and ESC/EACTS periodically review and update their guidelines for same, and these serve as a reference and guide for medical practitioners all over. Even though literature and evidence on offer is same, they sometimes differ in certain crucial aspects. This comparison serves to bring both on same page, allowing the reader to have a better understanding on the recommendations in particular situation, and the differences. This is especially true when it comes to left main disease, multivessel disease and significant left anterior descending artery stenosis. This comparison also serves to highlight the important role of coronary artery bypass in chronic coronary artery disease, as well as serving as a quick reference in case of dilemma.

• 1.   Organisation for Economic Co-operation and Development. Health at a glance.http://www. oecd.org/health/health-systems/health-at-a glance-19991312.htmaccessed July 21, 2018.
• 2.   Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS; Peer Review Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/ PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9 e119. doi: 10.1161/CIR.0000000000001168. Epub 2023 Jul 20. Erratum in: Circulation. 2023 Sep 26;148(13):e148. Erratum in: Circulation. 2023 Dec 5;148(23):e186. PMID: 37471501.
• 3.   Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/ eurheartj/ehy394. Erratum in: Eur Heart J. 2019 Oct 1;40(37):3096. PMID: 30165437.
• 4.   Byrne RA, Fremes S, Capodanno D, Czerny M, Doenst T, Emberson JR, Falk V, Gaudino M, McMurray JJV, Mehran R, Milojevic M, Uva MS. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. Eur J Cardiothorac Surg. 2023 Aug 1;64(2):ezad286. doi: 10.1093/ejcts/ezad286. PMID: 37632766.
• 5.   Writing Committee Members; Lawton JS, Tamis Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. J Am CollCardiol. 2022 Jan 18;79(2):e21-e129. doi: 10.1016/j.jacc.2021.09.006. Epub 2021 Dec 9. Erratum in: J Am CollCardiol. 2022 Apr 19;79(15):1547. PMID: 34895950.
• 6.   Thuijs DJFM, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled Syntax trial. Lancet. 2019;394:1325–1334.
• 7.   Mohr FW, Morice M-C, Kappetein AP, et al. Coronary artery bypass graftsurgery versus percutaneous coronary intervention in patients with threevesseldisease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629–638.
• 8.   Ono M, Serruys PW, Garg S, et al. Effect of patient reported pre-proceduralphysical and mental health on 10-year mortality after percutaneous or surgicalcoronary revascularization. Circulation. 2022;146:1268–1280.
• 9.   Salisbury AC, Kirtane AJ, Ali ZA, et al. The Outcomes of Percutaneous Revascularizationfor Management of SUrgically Ineligible Patients WithMultivesselor Left Main Coronary Artery Disease (OPTIMUM) registry: rationaleand design. CardiovascRevasc Med. 2022;41:83–91.
• 10.   Holm NR, Makikallio T, Lindsay MM, Spence MS, Erglis A, Menown IBA, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet 2020;395:191–9. https://doi.org/10.1016/ S0140-6736(19)32972-1.
• 11.   Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, et al. Five-Year outcomes after PCI or CABG for left main coronary disease. N Engl J Med 2019;381: 1820–30. https://doi.org/10.1056/ NEJMoa1909406.
• 12.   Park DW, Ahn JM, Park H, Yun SC, Kang DY, Lee PH, et al. Ten-Year outcomes after drug eluting stents versus coronary artery bypass grafting for left main coronary disease: extended follow-up of the Precombat trial. Circulation 2020;141:1437–46. https:// doi.org/10.1161/ CirculationAHA.120.046039.
• 13.   Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, Kang SJ, Lee SW, Lee CW,Park SW, Choo SJ, Chung CH, Lee JW, Cohen DJ, Yeung AC, Hur SH, SeungKB, Ahn TH, Kwon HM, Lim DS, Rha SW, Jeong MH, Lee BK, Tresukosol D, FuGS, Ong TK; BEST Trial Investigators. Trial of everolimus-eluting stents orbypass surgery for coronary disease. N Engl J Med 2015;372:1204–1212.
• 14.   Farkouh ME, Domanski M, Dangas GD, et al. Long-term survival followingmultivessel revascularization in patients with diabetes: the Freedom follow-on study. J Am CollCardiol. 2019;73:629–638.

Data Sharing Statement

Funding